Publication
Title
Nivolumab in squamous cell carcinoma of the head and neck
Author
Abstract
Introduction: The prognosis of recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) after failure of first line chemotherapy is dismal. Until the publication of the results of CheckMate 141, not a single agent provided any survival benefit as a second line treatment for R/M HNSCC.Areas covered: A comprehensive review of the literature was conducted on the role of nivolumab in HNSCC.Expert commentary: Nivolumab is approved by the Food and Drug Administration for the treatment of patients based on the results of CheckMate 141 showing an overall survival benefit as compared to standard care (single agent docetaxel, methotrexate, or cetuximab). Of particular interest are immune-related adverse events which should be managed according to published guidelines.
Language
English
Source (journal)
Expert review of anticancer therapy
Publication
2018
ISSN
1473-7140
Volume/pages
18:5(2018), p. 409-420
ISI
000429352500001
Pubmed ID
29560755
Full text (Publisher's DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 04.05.2018
Last edited 15.07.2021
To cite this reference